Scroll each row sideways. Dashed cards haven't happened yet.
Question 4, to legalize natural psychedelics, loses 57–43.
Signs $50M for ibogaine trials: "Texas is now leading the way." No drug company matched the money; the state is running trials itself.
Says psychedelic therapy could be available "within 12 months." The deadline passed without an approval.
Backs psychedelic research for veterans; the VA has funded its first psychedelic study since the 1960s.
Executive order to fast-track review, open Right to Try (including ibogaine) and fund state programs. Legalizes nothing.
Priority vouchers for Compass and Usona; floated approval by "end of summer." It didn't come.
111 psychedelic bills in 41 states this year; New Mexico's medical psilocybin program is due by end of 2027.
Resubmitted for PTSD without a new trial, two years after rejection.
Nonprofit, unpatented, for major depression. Could be the first approval.
Application due within weeks; launch targeted for early-to-mid 2027.
A modified psilocin for depression reports its first pivotal trial.
Three positive phase 3s in anxiety and depression; FDA application planned.
Inhaled, with short trips; pivotal trials begin after a strong phase 2.
An approved psilocybin drug still can't launch until the DEA moves it out of Schedule I.
Sources: Texas governor's office (June 2025); PBS NewsHour and Boston Globe on RFK Jr. (2025); STAT and Foley & Lardner on Executive Order 14401 (Apr 2026); NBC News and Fortune on FDA vouchers (Apr 2026); Compass Q3 2026 SEC filing; Psychedelic Alpha (Usona filing, single source); HCPLive (MDMA resubmission); MAPS 2026 legislative roundup.